Observational Study Investigates Optimal Liraglutide Timing for Post-Bariatric Surgery Obesity Management

Obesity remains a significant global health challenge, often requiring interventions like metabolic surgery for sustained weight loss and remission of comorbidities. While highly effective, a notable subset of patients experiences insufficient initial weight loss or subsequent weight regain, leading to persistent obesity. This can compromise the long-term benefits of surgery and necessitate further interventions. Current post-surgical management primarily focuses on lifestyle modifications, but pharmacological adjuncts are gaining importance. Glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide, have demonstrated robust efficacy in promoting weight loss and improving metabolic health by enhancing satiety, slowing gastric emptying, and reducing food intake. However, the optimal timing and integration of these powerful agents into the post-bariatric surgery care pathway, particularly for patients with suboptimal weight outcomes, remain an area of active investigation and clinical uncertainty. This observational study directly addresses this critical clinical gap.